Casdin Capital as of Sept. 30, 2017
Portfolio Holdings for Casdin Capital
Casdin Capital holds 26 positions in its portfolio as reported in the September 2017 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Loxo Oncology | 9.4 | $33M | 360k | 92.12 | |
Myokardia | 6.8 | $24M | 560k | 42.85 | |
Alnylam Pharmaceuticals (ALNY) | 6.6 | $24M | 200k | 117.49 | |
Sangamo Biosciences (SGMO) | 5.9 | $21M | 1.4M | 15.00 | |
Blueprint Medicines (BPMC) | 5.9 | $21M | 298k | 69.67 | |
Bluebird Bio (BLUE) | 5.6 | $20M | 145k | 137.35 | |
Foundation Medicine | 5.5 | $19M | 480k | 40.20 | |
Kite Pharma | 5.4 | $19M | 106k | 179.81 | |
Spark Therapeutics | 5.3 | $19M | 210k | 89.16 | |
Agios Pharmaceuticals (AGIO) | 4.8 | $17M | 255k | 66.75 | |
Voyager Therapeutics (VYGR) | 4.7 | $17M | 815k | 20.59 | |
Sage Therapeutics (SAGE) | 4.2 | $15M | 240k | 62.30 | |
GenMark Diagnostics | 4.1 | $14M | 1.5M | 9.63 | |
Evolent Health (EVH) | 4.0 | $14M | 795k | 17.80 | |
Global Blood Therapeutics In | 3.3 | $12M | 380k | 31.05 | |
Audentes Therapeutics | 3.2 | $11M | 400k | 28.01 | |
Clovis Oncology | 3.0 | $11M | 128k | 82.40 | |
Codexis (CDXS) | 2.8 | $9.8M | 1.5M | 6.65 | |
Illumina (ILMN) | 2.5 | $8.8M | 44k | 199.20 | |
Jounce Therapeutics | 1.8 | $6.2M | 400k | 15.58 | |
Tesaro | 1.4 | $5.0M | 39k | 129.09 | |
Syros Pharmaceuticals | 1.1 | $3.8M | 256k | 14.72 | |
Cytomx Therapeutics (CTMX) | 0.9 | $3.2M | 178k | 18.17 | |
Editas Medicine (EDIT) | 0.9 | $3.2M | 133k | 24.01 | |
Fate Therapeutics (FATE) | 0.6 | $2.2M | 550k | 3.96 | |
Ovid Therapeutics (OVID) | 0.5 | $1.8M | 208k | 8.57 |